PREVU cholesterol test trial
This article was originally published in The Tan Sheet
A clinical trial evaluating the PREVU Point of Care skin sterol test will measure the relationship between skin sterol values and already-established coronary artery disease markers such as ankle/brachial blood pressure index and vascular compliance, International Medical Innovations announces. The study will follow 100 patients at high risk for cardiovascular disease and not taking cholesterol-lowering medication. The product measures cholesterol levels that accumulate in skin tissue. McNeil Consumer & Specialty Pharmaceuticals reached a licensing agreement with IMI in June. The firms are developing PREVU predictive tests for medical, laboratory and home use (1"The Tan Sheet" June 7, 2004, p. 10)...
You may also be interested in...
McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?